Php72 - A New French Financial Incentive to Boost Insulin and Etanercept Biosimilars Prescribing: Simulation of Economic Impacts for the Public Hospitals of Paris

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.966
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

New Insulins, Biosimilars, and Insulin Therapy

Diabetes Technology and Therapeutics
MedicineEndocrinologyMedical Laboratory TechnologyMetabolismDiabetes
2020English

Licensing and Prescribing Biosimilars in Australia

GaBI Journal
Drug GuidesPharmacy
2013English

Pin86 - Cost Savings to Be Expected From the Introduction of New Anti-Hiv Generics in University Public Hospitals of Paris

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Cost Accounting as a Possible Solution for Financial Sustainability of Croatian Public Hospitals

Croatian Economic Survey
EconomicsEconometricsFinance
2016English

Source of Admission and Cost: Public Hospitals Face Financial Risk.

American Journal of Public Health
EnvironmentalPublic HealthOccupational Health
1986English

The Origins of New Quotative Expressions: The Case of Paris French

Journal of French Language Studies
LinguisticsLanguage
2018English

Impacts of the Chinese Sreb on Afghanistan Financial and Economic Impacts of the Chinese Silk Road Economic Belt Project on Afghanistan

Humanities and Social Sciences Reviews
ArtsSocial SciencesHumanities
2019English

Clinical Information Systems: Tools to Boost Prescribing Safety

Prescriber
Pharmacology
2017English

PSS14 Economic Analysis of Etanercept as Paused Therapy in Moderate to Severe Psoriasis From a Public Perspective in Brazil

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy